340B to Be Key Agenda Item for Biden’s New HHS General Counsel Pick

President Biden has nominated civil rights attorney Sam Bagenstos to be HHS General Counsel.

President Biden has nominated current White House Office of Management and Budget (OMB) General Counsel Sam Bagenstos to be the U.S. Health and Human Services Department (HHS) General Counsel—a post that has had a growing role in defending the 340B

Read More »

Biden Lays Down Markers for Action to Lower Drug Prices

President Biden this morning called on Congress to let Medicare negotiate drug prices and make drug companies that raise their prices faster than inflation pay a penalty.

President Biden this morning called on Congress to let Medicare negotiate drug prices and penalize drug companies that raise their prices faster than inflation.

Biden said lawmakers should establish a firm cap on the amount that Medicare beneficiaries have to

Read More »

U.S. Senate Sets Stage for Action on Lowering Drug Prices

U.S. Senate Democrats, led by Chuck Schumer (N.Y.), are setting the stage for a vote soon on policy changes to lower drug prices.

The U.S. Senate on Tuesday voted 69-30 to pass a bipartisan infrastructure bill that includes two drug pricing provisions, neither directly 340B-related. The bill now moves to the U.S. House, which is on a seven-week summer break. The $1 trillion

Read More »

PhRMA Urges Court Again to Strike Down 340B Dispute Resolution Process

PhRMA's lawsuit challenging the 340B administrative dispute resolution process is being heard in federal district court in Baltimore.

Regulations establishing a binding administrative dispute resolution (ADR) process for the 340B program were rushed into place last December to defeat lawsuits, are fatally flawed legally and constitutionally, and should be struck down, the main U.S. trade association for drug

Read More »

Biden Wants to Rescind Trump’s Most Favored Nation Proposal That Received Widespread Criticism from Drug Industry and 340B Providers

The Biden administration plans to rescind ex-President Trump's Most Favored Nation interim final rule that would peg Medicare reimbursement for some drugs to the lowest price that drug manufacturers get in similar countries.

The Biden administration plans to rescind a published but unimplemented Trump-era regulation that would peg Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers get in similar countries. The widely criticized regulation

Read More »

In Fight with National Implications, Calif. 340B Providers Try to Stop Move That Could Result in Millions of Lost Savings

California Gov. Gavin Newsom's twice-delayed executive order that would slash Medicaid reimbursement for 340B-purchased drugs is back on track.

California’s twice-postponed shift of Medicaid (Medi-Cal) managed care prescription drug benefits to Medi-Cal fee for service (FFS) is back on for Jan. 1, 2022, one year later than originally planned.

A similar high-stakes battle over Medicaid reimbursement for 340B-purchased drugs

Read More »

Wisconsin Lawmakers Introduce 340B Anti-Discrimination Measure but Leave Out Most 340B Hospitals

Wisconsin Gov. Tony Evers (D) is pushing for passage of legislation to eliminate payer and pharmacy benefit manager (PBM) discrimination against health centers, critical access hospitals, Ryan White HIV/AIDS program grantees, and their contract pharmacies.

Wisconsin Gov. Tony Evers (D) is pushing for passage of a package of 13 “Less for Rx” bills to control prescription drug costs, including one to eliminate payer and pharmacy benefit manager (PBM) discrimination against certain 340B covered entities.

The

Read More »

Contrary to Reports, Judge in AstraZeneca Lawsuit Did Not Strike Down 340B Unlimited Contract Pharmacy, Court Clerk Says

U.S. Chief District Judge Leonard Stark did not rule that AstraZeneca is not required to deliver 340B discounts drugs to an unlimited number of contract pharmacies, the court clerk's office said today.

The clerk of the federal district court in Wilmington, Del., confirmed this morning that a judge did not rule that drug manufacturer AstraZeneca is not required to deliver 340B discounts drugs to an unlimited number of contract pharmacies. There were

Read More »

Insulin Manufacturers Colluded on 340B Contract Pharmacy After Joint Lobbying Push Failed, Lawsuit Alleges

Four insulin manufacturers conspired to deny 340B discounts on their products shipped to contract pharmacies after an effort to lobby the Trump administration failed, a lawsuit alleges.

CORRECTION Thursday, Aug. 5, 2021, 8:15 p.m.—Earlier today, we misdescribed Novo Nordisk’s 340B contract pharmacy policy. Beginning on Jan. 1, 2021, Novo Nordisk stopped facilitating bill to/ship to distribution of 340B product to hospital contract pharmacies. We incorrectly said Novo

Read More »

340B Report Publisher and CEO Says New Bipartisan 340B Bill is Win for Providers and Drug Industry

The PROTECT 340B solves "two of the most intractable challenges in the 340B program in one fell swoop," 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.

U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live